AXDX - アクセレレ―ト・ダイアグノスティックス (Accelerate Diagnostics Inc.) アクセレレ―ト・ダイアグノスティックス

 AXDXのチャート


 AXDXの企業情報

symbol AXDx
会社名 Accelerate Diagnostics Inc (アクセレレ―ト・ダイアグノスティックス)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 アクセレレイト・ダイアグノスティクス(Accelerate Diagnostics Inc.)は重大な感染症の診断を通じて患者のアウトカムを開発するソリューションを提供するインビトロ診断会社である。同社のin vitro診断プラットフォームであるAccelerate Phenoシステムは、生細菌または真菌細胞が特定の抗生物質に耐性かまたは感受性かを決定する抗生物質感受性試験(AST)を行うための遺伝子型技術(ID)、感染性病原体および表現型技術を利用する 。同社は単一の患者サンプルから直接病原体を検出・同定し、続いて同定結果に基づいて抗菌剤感受性試験を行う。Accelerate PhenoTest BCキットは、高い罹患率と死亡リスクを伴う生命を脅かす状態である菌血症または真菌血症の疑いのある患者に、IDとASTの結果を提供する。Accelerate Phenoシステムは、ウォークアウェイの自動化を特長とし、固定計測器と一回使用のテストキットで構成される。   アクセレレ―ト・ダイアグノスティックスは米国で医療診断機器を製造、販売。「ID/ASTシステム」の名前で感染性病原体の同定と薬剤感受性試験向け機器、検査キットを提供。敗血症と呼吸器感染などの診断のためにグラム陽性菌とグラム陰性菌の抗生物質への感受性を検査。   Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
本社所在地 3950 South Country Club Road Suite 470 Tucson AZ 85714 USA
代表者氏名 John Patience ジョン・ペイシェンス
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-863-8088
設立年月日 30072
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 239人
url www.acceleratediagnostics.com
nasdaq_url https://www.nasdaq.com/symbol/axdx
adr_tso
EBITDA EBITDA(百万ドル) -72.46400
終値(lastsale) 18.4197
時価総額(marketcap) 997021337.403
時価総額 時価総額(百万ドル) 974.57450
売上高 売上高(百万ドル) 5.44000
企業価値(EV) 企業価値(EV)(百万ドル) 892.66950
当期純利益 当期純利益(百万ドル) -77.40700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Accelerate Diagnostics Inc revenues increased from $1.2M to $2.5M. Net loss increased 44% to $44M. Revenues reflect Domestic(United States) segment increase of 71% to $1.8M Foreign-World ex-United States (Region) segment increase from $167K to $678K. Higher net loss reflects Other Sales general and administrative increase of 48% to $23.2M (expense).

 AXDXのテクニカル分析


 AXDXのニュース

   Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind  2022/04/02 13:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.81 million, with the beta value of the company hitting 1.82. At the end of the trading day, the stock’s price was $1.41, reflecting an intraday loss of -2.08% or -$0.03. The 52-week high for the AXDX share is $9.42, that puts it down … Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind Read More »
   Accelerate Diagnostics launches Accelerate Arc system for use in blood culture test  2022/03/28 14:50:12 Seeking Alpha
Accelerate Diagnostics (AXDX) launched its blood culture testing product Accelerate Arc system, that comprises of the Arc Module and BC Kit. The product is designed for labs and is a…
   Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week?  2022/03/12 12:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.79, reflecting an intraday loss of -5.29% or -$0.1. The 52-week high for the AXDX share is $9.79, that puts it down … Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week? Read More »
   Accelerate Diagnostics'' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript  2022/03/09 02:29:05 Seeking Alpha
   Accelerate Diagnostics reports Q4 results (NASDAQ:AXDX)  2022/03/08 21:34:22 Seeking Alpha
Accelerate Diagnostics press release (AXDX): Q4 GAAP EPS of -$0.34.Revenue of $3.3M (+6.5% Y/Y).
   Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind  2022/04/02 13:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.81 million, with the beta value of the company hitting 1.82. At the end of the trading day, the stock’s price was $1.41, reflecting an intraday loss of -2.08% or -$0.03. The 52-week high for the AXDX share is $9.42, that puts it down … Accelerate Diagnostics Inc. (NASDAQ: AXDX) Rose 4.26% From Its 52-Week Low; YTD Numbers Fall -72.99% – Here Are Some Things To Keep In Mind Read More »
   Accelerate Diagnostics launches Accelerate Arc system for use in blood culture test  2022/03/28 14:50:12 Seeking Alpha
Accelerate Diagnostics (AXDX) launched its blood culture testing product Accelerate Arc system, that comprises of the Arc Module and BC Kit. The product is designed for labs and is a…
   Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week?  2022/03/12 12:30:00 Marketing Sentinel
During the last session, Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s traded shares were 0.42 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.79, reflecting an intraday loss of -5.29% or -$0.1. The 52-week high for the AXDX share is $9.79, that puts it down … Is Accelerate Diagnostics Inc. (NASDAQ: AXDX) Still A Buy After sinking -23.50% Last Week? Read More »
   Accelerate Diagnostics'' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript  2022/03/09 02:29:05 Seeking Alpha
   Accelerate Diagnostics reports Q4 results (NASDAQ:AXDX)  2022/03/08 21:34:22 Seeking Alpha
Accelerate Diagnostics press release (AXDX): Q4 GAAP EPS of -$0.34.Revenue of $3.3M (+6.5% Y/Y).
   Accelerate Diagnostics slips 3% as prelim 4Q FY21 revenue expected to be below consensus  2022/01/13 14:29:31 Seeking Alpha
Accelerate Diagnostics (AXDX) slips 3% as 4Q revenue is expected to be ~$3.3M (consensus $3.75M) compared to $3.1M in 4Q20.FY21 revenue is expected to be $11.8M (consensus…
   Accelerate Diagnostics (NASDAQ:AXDX) Upgraded to Hold at Zacks Investment Research  2021/12/15 23:04:41 Dakota Financial News
Accelerate Diagnostics (NASDAQ:AXDX) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, []
   Contrasting Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX)  2021/12/13 09:00:43 ETF Daily News
Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership. Institutional & Insider Ownership 71.3% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, [] The post Contrasting Nautilus Biotechnology (NASDAQ:NAUT) and Accelerate Diagnostics (NASDAQ:AXDX) appeared first on ETF Daily News .
   Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Shares Acquired by Goldman Sachs Group Inc.  2021/12/08 09:06:46 Dakota Financial News
Goldman Sachs Group Inc. grew its position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 49.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,526 shares of the medical research companys stock after purchasing an additional 16,005 shares during the period. Goldman Sachs Group Inc. owned approximately []
   Accelerate Diagnostics Inc.s (AXDX) -0.80% Retreat Justifies A Second Look  2021/12/04 16:30:00 Stocks Register
Accelerate Diagnostics Inc. (NASDAQ:AXDX) concluded the trading at $4.97 on Friday, December 03 with a fall of -0.80% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $5.01 and 5Y monthly beta was reading 1.88 with its price kept floating in the Accelerate Diagnostics Inc.s (AXDX) -0.80% Retreat Justifies A Second Look Read More »

 関連キーワード  (先端医療機器_テクノロジ― 米国株 アクセレレ―ト・ダイアグノスティックス AXDX Accelerate Diagnostics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)